In April 2010 the US Food and Drug Administration (FDA) sent a warning letter detailing current good manufacturing practice (cGMP) violations to Perrigo. Concerns raised in the letter included failure to perform full investigations when a batch or its components didn’t meet specifications.
As part of the follow-up process FDA inspectors from the Detroit office are visiting the Allegan site, says Perrigo.